CTLA4 and neoplasm: ICIs, functioning through interrupting the suppressive signals transduced by CTLA4 or PD1 to reactivate the anti-tumor immunity and prevent tumor immune evasion, was approved to be successful in the treatment of multiple cancers (Sharma and Allison, 2015).